Skip to main content
main-content
Top

13-01-2022 | Rheumatology | News | Article

approvalsWatch

NICE recommends upadacitinib for some PsA patients

Author:
Claire Barnard

medwireNews: The National Institute for Health and Care Excellence has recommended upadacitinib as a treatment option for certain patients with active psoriatic arthritis (PsA) in England and Wales.

The selective Janus kinase 1 inhibitor may now be used for adult patients with peripheral PsA and at least three tender and three swollen joints despite prior treatment. To be eligible for upadacitinib patients must either:

have an inadequate response to at least two conventional DMARDs and one biologic DMARD; orhave a contraindication to tumor necrosis factor inhibitors when they would otherwise be considered.

The benefits of upadacitinib for people with PsA were demonstrated in the SELECT-PsA-1 and SELECT-PsA-2 trials.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

See the research in context now

with trial summaries, expert opinion and congress coverage